Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beam Therapeutics Inc
(NQ:
BEAM
)
26.81
+2.29 (+9.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beam Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
February 07, 2023
From
Beam Therapeutics
Via
GlobeNewswire
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
February 06, 2023
Cathie Wood is bullish about these stocks. And so are Wall Street analysts.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
February 01, 2023
Via
Benzinga
Analyst Ratings for Beam Therapeutics
February 01, 2023
Via
Benzinga
4 Analysts Have This to Say About Beam Therapeutics
December 20, 2022
Via
Benzinga
BMO Capital Upgrades Beam Therapeutics: Here's What You Need To Know
December 20, 2022
Via
Benzinga
Beam Therapeutics's Return On Capital Employed Insights
November 30, 2022
Via
Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
Via
InvestorPlace
5 Top Stocks for February
January 29, 2023
These growth stocks have more room to run.
Via
The Motley Fool
3 Great Growth Stocks Down 20% or More to Buy Now
January 27, 2023
These beaten-down stocks could be poised for major rebounds.
Via
The Motley Fool
A New Bull Market Is Coming: 3 Stocks That Could Skyrocket
January 21, 2023
Aggressive investors should check out these stocks.
Via
The Motley Fool
3 Stocks That Could Create Lasting Generational Wealth
January 15, 2023
Making money that spans generations requires thinking big.
Via
The Motley Fool
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones
January 09, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'
January 04, 2023
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams.
Via
Benzinga
Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Beam Therapeutics
Via
GlobeNewswire
3 Under-the-Radar Biotech Stocks to Buy in 2022
December 24, 2022
The attraction of all three biotech stocks is their potential.
Via
The Motley Fool
Analyst Beefs Up Beam Therapeutics Price Target, Says 'Reward Is Now Skewed To Upside'
December 20, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
December 20, 2022
Via
Benzinga
Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday
December 20, 2022
Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to close...
Via
Benzinga
7 ‘Next Big Things’ for Investors to Buy for 2023
December 13, 2022
The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown.
Via
InvestorPlace
Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant
December 10, 2022
Data from ESCAPE-1 and ESCAPE-2 Approaches to Be Presented During Poster Sessions at the 64th ASH Annual Meeting and Exposition
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
December 02, 2022
Beam Ranked No. 4 in Large Companies Category, Marking Fourth Consecutive Year as Top Workplace in Massachusetts
From
Beam Therapeutics
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022
December 13, 2022
Via
Benzinga
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts
December 02, 2022
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding...
Via
Benzinga
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
December 02, 2022
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference
November 30, 2022
From
Beam Therapeutics
Via
GlobeNewswire
A Sitcom Character Inspired This Investor
November 26, 2022
Plus, a look at the "Buffett premium" that investors give to Berkshire Hathaway stock.
Via
The Motley Fool
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
November 14, 2022
BEAM-101 BEACON Trial Represents the First Clinical Trial of a Base Editor in the United States
From
Beam Therapeutics
Via
GlobeNewswire
Unity Software, Amazon, Doximity And Other Big Gainers From Friday
November 14, 2022
U.S. stocks closed higher on Friday, with the Nasdaq Composite jumping more than 200 points. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
Beam Therapeutics to Participate in Upcoming Investor Conferences
November 09, 2022
From
Beam Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.